MXPA04004998A - Metodos para tratar cancer mediante la utilizacion de una combinacion de un antagonista del factor inhibidor de celula dentritica derivado de tumor y un antagonista del receptor de tipo toll. - Google Patents
Metodos para tratar cancer mediante la utilizacion de una combinacion de un antagonista del factor inhibidor de celula dentritica derivado de tumor y un antagonista del receptor de tipo toll.Info
- Publication number
- MXPA04004998A MXPA04004998A MXPA04004998A MXPA04004998A MXPA04004998A MX PA04004998 A MXPA04004998 A MX PA04004998A MX PA04004998 A MXPA04004998 A MX PA04004998A MX PA04004998 A MXPA04004998 A MX PA04004998A MX PA04004998 A MXPA04004998 A MX PA04004998A
- Authority
- MX
- Mexico
- Prior art keywords
- antagonist
- tumor
- tlr
- cpg
- antibody
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 251
- 201000011510 cancer Diseases 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title abstract description 23
- 239000005557 antagonist Substances 0.000 claims abstract description 94
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 49
- 239000000427 antigen Substances 0.000 claims abstract description 44
- 102000036639 antigens Human genes 0.000 claims abstract description 44
- 108091007433 antigens Proteins 0.000 claims abstract description 44
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 20
- 230000003213 activating effect Effects 0.000 claims abstract description 9
- 239000000556 agonist Substances 0.000 claims description 75
- 239000003112 inhibitor Substances 0.000 claims description 35
- 102000003814 Interleukin-10 Human genes 0.000 claims description 34
- 108090000174 Interleukin-10 Proteins 0.000 claims description 34
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 31
- 230000003308 immunostimulating effect Effects 0.000 claims description 29
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 239000002773 nucleotide Substances 0.000 claims description 21
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 17
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 17
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 16
- 239000003446 ligand Substances 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 16
- 108010012236 Chemokines Proteins 0.000 claims description 14
- 102000019034 Chemokines Human genes 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 201000001441 melanoma Diseases 0.000 claims description 12
- 230000004048 modification Effects 0.000 claims description 12
- 238000012986 modification Methods 0.000 claims description 12
- 150000003384 small molecules Chemical class 0.000 claims description 10
- 101150013553 CD40 gene Proteins 0.000 claims description 9
- 102000004551 Interleukin-10 Receptors Human genes 0.000 claims description 8
- 108010017550 Interleukin-10 Receptors Proteins 0.000 claims description 8
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 8
- 229940104302 cytosine Drugs 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- -1 CCL3 Proteins 0.000 claims description 7
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 7
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims description 5
- 108010029697 CD40 Ligand Proteins 0.000 claims description 5
- 102100032937 CD40 ligand Human genes 0.000 claims description 5
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000001875 tumorinhibitory effect Effects 0.000 claims description 4
- 102100023702 C-C motif chemokine 13 Human genes 0.000 claims description 3
- 102100023700 C-C motif chemokine 16 Human genes 0.000 claims description 3
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims description 3
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 3
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims description 3
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 claims description 3
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 claims description 3
- 101710190709 Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 claims description 3
- 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 claims description 3
- 101000978375 Homo sapiens C-C motif chemokine 16 Proteins 0.000 claims description 3
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims description 3
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 claims description 3
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims description 3
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 claims description 3
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims description 3
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 3
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 3
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims description 3
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 3
- 101800001271 Surface protein Proteins 0.000 claims description 3
- 108010017842 Telomerase Proteins 0.000 claims description 3
- 101710132062 Transitional endoplasmic reticulum ATPase Proteins 0.000 claims description 3
- 102000003425 Tyrosinase Human genes 0.000 claims description 3
- 108060008724 Tyrosinase Proteins 0.000 claims description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 230000001394 metastastic effect Effects 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229940044551 receptor antagonist Drugs 0.000 claims description 3
- 239000002464 receptor antagonist Substances 0.000 claims description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 3
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims description 2
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 2
- 102100021933 C-C motif chemokine 25 Human genes 0.000 claims description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 2
- 102100034871 C-C motif chemokine 8 Human genes 0.000 claims description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 2
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims description 2
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims description 2
- 101000897486 Homo sapiens C-C motif chemokine 25 Proteins 0.000 claims description 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 2
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 claims description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 2
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 claims description 2
- 101000972284 Homo sapiens Mucin-3A Proteins 0.000 claims description 2
- 101000972286 Homo sapiens Mucin-4 Proteins 0.000 claims description 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 2
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 102100034263 Mucin-2 Human genes 0.000 claims description 2
- 102100022497 Mucin-3A Human genes 0.000 claims description 2
- 102100022693 Mucin-4 Human genes 0.000 claims description 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 2
- 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 claims description 2
- 108010035075 Tyrosine decarboxylase Proteins 0.000 claims description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 230000000112 colonic effect Effects 0.000 claims description 2
- 230000002357 endometrial effect Effects 0.000 claims description 2
- 150000002270 gangliosides Chemical class 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 230000002440 hepatic effect Effects 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000002381 testicular Effects 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 101000633756 Echis pyramidum leakeyi Snaclec 4 Proteins 0.000 claims 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 1
- 101150084044 P gene Proteins 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000002089 prostaglandin antagonist Substances 0.000 claims 1
- 230000004913 activation Effects 0.000 abstract description 37
- 230000028993 immune response Effects 0.000 abstract description 15
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 241000124008 Mammalia Species 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 2
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 abstract 1
- 102000002689 Toll-like receptor Human genes 0.000 description 59
- 108020000411 Toll-like receptor Proteins 0.000 description 59
- 241000699670 Mus sp. Species 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 32
- 239000002158 endotoxin Substances 0.000 description 30
- 229920006008 lipopolysaccharide Polymers 0.000 description 30
- 102000013462 Interleukin-12 Human genes 0.000 description 28
- 108010065805 Interleukin-12 Proteins 0.000 description 28
- 229940076144 interleukin-10 Drugs 0.000 description 28
- 229940117681 interleukin-12 Drugs 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 11
- 210000001185 bone marrow Anatomy 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 9
- 230000004936 stimulating effect Effects 0.000 description 9
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 8
- 229960000905 indomethacin Drugs 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 201000009030 Carcinoma Diseases 0.000 description 6
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 6
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 6
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 230000002601 intratumoral effect Effects 0.000 description 6
- 239000006249 magnetic particle Substances 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 102000006992 Interferon-alpha Human genes 0.000 description 5
- 108010047761 Interferon-alpha Proteins 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000005748 tumor development Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 102100022297 Integrin alpha-X Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 229960002986 dinoprostone Drugs 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000002559 palpation Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- 238000003307 slaughter Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 101150014742 AGE1 gene Proteins 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010040721 Flagellin Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 101150016096 17 gene Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Substances OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
- 229940123189 CD40 agonist Drugs 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 101100045694 Caenorhabditis elegans art-1 gene Proteins 0.000 description 1
- 108010083702 Chemokine CCL21 Proteins 0.000 description 1
- 102000006435 Chemokine CCL21 Human genes 0.000 description 1
- 241000984642 Cura Species 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101001083151 Homo sapiens Interleukin-10 receptor subunit alpha Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 102100030236 Interleukin-10 receptor subunit alpha Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241001049120 Melanis Species 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 108010027090 biotin-streptavidin complex Proteins 0.000 description 1
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 108010039524 chondroitin sulfate proteoglycan 4 Proteins 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 108040006870 interleukin-10 receptor activity proteins Proteins 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33343401P | 2001-11-27 | 2001-11-27 | |
| PCT/US2002/038098 WO2003045431A2 (en) | 2001-11-27 | 2002-11-26 | Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04004998A true MXPA04004998A (es) | 2005-04-08 |
Family
ID=23302758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04004998A MXPA04004998A (es) | 2001-11-27 | 2002-11-26 | Metodos para tratar cancer mediante la utilizacion de una combinacion de un antagonista del factor inhibidor de celula dentritica derivado de tumor y un antagonista del receptor de tipo toll. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20030138413A1 (enExample) |
| EP (1) | EP1450858A2 (enExample) |
| JP (3) | JP2006502080A (enExample) |
| CN (1) | CN1617742B (enExample) |
| AU (1) | AU2002359516B2 (enExample) |
| BR (1) | BR0214457A (enExample) |
| CA (1) | CA2468320A1 (enExample) |
| HU (1) | HUP0500999A2 (enExample) |
| MX (1) | MXPA04004998A (enExample) |
| NO (1) | NO20042697L (enExample) |
| NZ (1) | NZ565420A (enExample) |
| TW (1) | TW200303759A (enExample) |
| WO (1) | WO2003045431A2 (enExample) |
| ZA (1) | ZA200404113B (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| DK1077722T3 (da) | 1998-05-22 | 2006-11-27 | Ottawa Health Research Inst | Fremgangsmåder og produkter til induktion af mukosaimmunitet |
| US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| WO2001051500A1 (en) | 2000-01-14 | 2001-07-19 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| US20010044416A1 (en) * | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
| US20040175355A1 (en) * | 2001-04-18 | 2004-09-09 | The Regents Of The University Of California | Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals |
| US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
| US7354909B2 (en) * | 2001-08-14 | 2008-04-08 | The United States Of America As Represented By Secretary Of The Department Of Health And Human Services | Method for rapid generation of mature dendritic cells |
| EP1450856B1 (en) | 2001-09-14 | 2009-11-11 | Cytos Biotechnology AG | Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use |
| AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
| US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
| US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
| US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
| US7387271B2 (en) * | 2002-12-30 | 2008-06-17 | 3M Innovative Properties Company | Immunostimulatory combinations |
| US8795672B2 (en) * | 2003-02-14 | 2014-08-05 | University Of Southern California | Compositions and methods for cancer immunotherapy |
| CN101675993A (zh) | 2003-03-26 | 2010-03-24 | 赛托斯生物技术公司 | Melan-a肽类似物-病毒样颗粒偶联物 |
| US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
| WO2005014110A1 (en) * | 2003-07-22 | 2005-02-17 | Cytos Biotechnology Ag | Cpg-packaged liposomes |
| ES2689328T3 (es) | 2004-01-07 | 2018-11-13 | Novartis Vaccines And Diagnostics, Inc. | Anticuerpo monoclonal M-CSF-específico y usos del mismo |
| JP2007526253A (ja) * | 2004-02-19 | 2007-09-13 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 免疫刺激性ウイルスｒｎａオリゴヌクレオチド |
| JP2008522951A (ja) * | 2004-07-19 | 2008-07-03 | ベイラー・カレツジ・オブ・メデイシン | サイトカインシグナル伝達調節物質の調節および免疫療法のための応用 |
| WO2006014653A1 (en) * | 2004-07-20 | 2006-02-09 | Schering Corporation | Induction of apoptosis in toll-like receptor expressing tumor cells |
| WO2007050095A2 (en) | 2004-11-19 | 2007-05-03 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
| JPWO2006077724A1 (ja) * | 2004-12-28 | 2008-06-19 | 株式会社イミュノフロンティア | がんワクチン製剤 |
| EP1712241A1 (en) * | 2005-04-15 | 2006-10-18 | Centre National De La Recherche Scientifique (Cnrs) | Composition for treating cancer adapted for intra-tumoral administration and uses thereof |
| US20100143899A1 (en) * | 2005-05-17 | 2010-06-10 | University Of Vermont And State Agricultural College | Methods and products for diagnosing cancer |
| CN101501055B (zh) * | 2005-06-23 | 2016-05-11 | 贝勒医学院 | 负性免疫调节因子的调节和免疫疗法应用 |
| EP1906989A4 (en) * | 2005-07-11 | 2009-08-19 | Cbio Ltd | IMMUNOMODULATION INDUCED BY CHAPERONIN 10 |
| NZ569086A (en) * | 2005-12-01 | 2011-07-29 | Trinity College Dublin | Compositions comprising a Toll-like receptor (TLR) agonist and an immune modulator for treating Th1-mediated conditions, such as cancer and infectious diseases |
| AU2006325225B2 (en) | 2005-12-14 | 2013-07-04 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| SI2032592T1 (sl) | 2006-06-12 | 2013-10-30 | Cytos Biotechnology Ag | Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov |
| DE102006035618A1 (de) * | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
| US20080124366A1 (en) * | 2006-08-06 | 2008-05-29 | Ohlfest John R | Methods and Compositions for Treating Tumors |
| US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
| EP2079305A4 (en) * | 2006-12-12 | 2010-01-27 | Idera Pharmaceuticals Inc | SYNTHETIC AGONISTS OF TLR9 |
| WO2008134020A1 (en) * | 2007-04-26 | 2008-11-06 | University Of Vermont And State Agricultural College | Ccl18 and ccl3 methods and compositions for detecting and treating cancer |
| EP2222344A4 (en) * | 2007-11-30 | 2012-11-07 | Baylor College Medicine | VACCINATE COMPOSITIONS WITH DENDRITIC CELLS AND THEIR USE |
| JP2012516352A (ja) * | 2009-01-30 | 2012-07-19 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｌｒ９の合成アゴニスト |
| JP5950824B2 (ja) | 2009-12-07 | 2016-07-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗腫瘍抗体療法を増強するための方法 |
| WO2011097384A2 (en) * | 2010-02-04 | 2011-08-11 | Board Of Regents, The University Of Texas System | Tumor targeted delivery of immunomodulators by nanoplymers |
| US20130108661A1 (en) | 2010-02-05 | 2013-05-02 | Mount Sinai School Of Medicine | Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells |
| US9890202B2 (en) | 2010-07-19 | 2018-02-13 | Yeda Research And Development Co. Ltd. | Peptides based on the transmembrane domain of a toll-like receptor (TLR) for treatment of TLR-mediated diseases |
| KR20130108295A (ko) * | 2010-08-13 | 2013-10-02 | 베일러 리서치 인스티튜트 | 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제 |
| EP2858722B8 (en) * | 2012-06-08 | 2018-02-21 | Aduro BioTech, Inc. | Compostions and methods for cancer immunotherapy |
| RU2678083C2 (ru) * | 2012-06-27 | 2019-01-23 | Кенитиро Хасуми | Терапия и способ внутриопухолевого введения цитотоксического т-лимфоцита и/или nkt-клетки с антителом против tnf и/или антителом против il-10 |
| CN104603156B (zh) | 2012-09-05 | 2016-10-26 | 中外制药株式会社 | 引入有氨基酸和甾基的透明质酸衍生物 |
| CN103768604B (zh) * | 2012-10-24 | 2016-03-30 | 北京圣沃德生物科技有限公司 | 治疗性肿瘤疫苗 |
| SG11201502796RA (en) | 2012-12-13 | 2015-05-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| CN103013915B (zh) * | 2013-01-09 | 2014-05-28 | 高岱清 | 一种高活性负载抗原的树突状细胞的制备方法 |
| JP2016524593A (ja) | 2013-04-29 | 2016-08-18 | メモリアル スローン−ケタリング キャンサー センター | セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法 |
| CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| EP2996472B1 (en) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| CA2919268C (en) | 2013-07-25 | 2023-09-05 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| US10176292B2 (en) | 2013-07-31 | 2019-01-08 | Memorial Sloan-Kettering Cancer Center | STING crystals and modulators |
| AU2015269412B2 (en) | 2014-06-04 | 2020-03-12 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| WO2016081911A2 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| AU2016251687C1 (en) | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
| PT3291821T (pt) * | 2015-05-07 | 2026-03-18 | Baylor College Medicine | Imunoterapêutica com células dendríticas |
| EP3292152A1 (en) | 2015-05-07 | 2018-03-14 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| MX2017015311A (es) * | 2015-05-29 | 2018-06-19 | Merck Sharp & Dohme | Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer. |
| KR102779525B1 (ko) * | 2015-05-29 | 2025-03-12 | 다이나박스 테크놀로지 코퍼레이션 | 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여 |
| US20200079860A1 (en) * | 2015-08-06 | 2020-03-12 | Memorial Sloan Kettering Cancer Center | Methods and compositions for tumor therapy |
| TW201716084A (zh) * | 2015-08-06 | 2017-05-16 | 葛蘭素史克智慧財產發展有限公司 | 組合物及其用途與治療 |
| CR20180229A (es) | 2015-10-29 | 2018-08-24 | Novartis Ag | Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll |
| WO2017096179A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| WO2017192470A1 (en) * | 2016-05-03 | 2017-11-09 | Merck Sharp & Dohme Corp. | Combination therapy of anti-il-10 antibody and compositions comprising lipid nanoparticles and tlr9 agonist cpg oligonucleotides |
| WO2017214706A1 (en) * | 2016-06-15 | 2017-12-21 | Tissue Regeneration Therapeutics Inc. | Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc) |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| WO2018060513A1 (en) | 2016-09-30 | 2018-04-05 | Galderma Research & Development | Methods and compositions for treating precancerous lesions or cancer comprising tlr/tlr or tlr/clr agonists |
| WO2018060514A1 (en) | 2016-09-30 | 2018-04-05 | Galderma Research & Development | Methods and compositions combining at least one pattern recognition receptor (prr) agonist with an anti-il10 receptor antibody |
| CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| IL268744B2 (en) * | 2017-02-17 | 2024-08-01 | Aivita Biomedical Inc | Methods for increasing the immunogenicity of tumors and preparations for autologous immunotherapeutic products against cancer using tumor cells and adapted dendritic cells |
| EP3635410A4 (en) * | 2017-06-04 | 2021-03-10 | Rappaport Family Institute for Research in the Medical Sciences | PROCEDURE FOR PREDICTING PERSONALIZED RESPONSE TO CANCER TREATMENT USING IMMUNE CHECKPOINT INHIBITORS AND KITS |
| WO2019246111A1 (en) * | 2018-06-19 | 2019-12-26 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Oncolytic virus or antigen presenting cell mediated cancer therapy using type i interferon and cd40-ligand |
| CN113005090A (zh) * | 2019-12-20 | 2021-06-22 | 上海细胞治疗集团有限公司 | 共表达趋化因子和共刺激分子的dc细胞及其应用 |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| US20230210968A1 (en) * | 2020-06-11 | 2023-07-06 | Massachusetts Institute Of Technology | Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy |
| KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7397887A (en) * | 1986-05-09 | 1987-12-01 | Sloan-Kettering Institute For Cancer Research | Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment |
| JPH08504766A (ja) * | 1992-12-14 | 1996-05-21 | スタート テクノロジー パートナーシップ | ドーパミン作動性神経系の病態の診断および治療に関するドーパミン受容体ｍＲＮＡに対してアンチセンスのオリゴヌクレオチドの投与 |
| AUPM322393A0 (en) * | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| AU713040B2 (en) * | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| US6071535A (en) * | 1996-01-31 | 2000-06-06 | Collaborative Laboratories, Inc. | Lipid vesicles formed with alkylammonium fatty acid salts |
| WO1998016247A1 (en) * | 1996-10-11 | 1998-04-23 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| US7390619B1 (en) * | 1998-02-11 | 2008-06-24 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
| US6218371B1 (en) * | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| DK1187629T3 (da) * | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid |
| EP1261366A4 (en) * | 2000-02-24 | 2003-06-18 | Univ Leland Stanford Junior | ADJUVANT TREATMENT BY IN VIVO ACTIVATION OF DENDRITIC CELLS |
| EP1283722A1 (en) * | 2000-03-31 | 2003-02-19 | Idec Pharmaceuticals Corporation | Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma |
-
2002
- 2002-11-25 TW TW091134176A patent/TW200303759A/zh unknown
- 2002-11-26 HU HU0500999A patent/HUP0500999A2/hu unknown
- 2002-11-26 EP EP02794058A patent/EP1450858A2/en not_active Withdrawn
- 2002-11-26 US US10/304,616 patent/US20030138413A1/en not_active Abandoned
- 2002-11-26 WO PCT/US2002/038098 patent/WO2003045431A2/en not_active Ceased
- 2002-11-26 AU AU2002359516A patent/AU2002359516B2/en not_active Ceased
- 2002-11-26 JP JP2003546932A patent/JP2006502080A/ja active Pending
- 2002-11-26 NZ NZ565420A patent/NZ565420A/en not_active IP Right Cessation
- 2002-11-26 CA CA002468320A patent/CA2468320A1/en not_active Abandoned
- 2002-11-26 BR BRPI0214457-3A patent/BR0214457A/pt not_active IP Right Cessation
- 2002-11-26 CN CN028275985A patent/CN1617742B/zh not_active Expired - Fee Related
- 2002-11-26 MX MXPA04004998A patent/MXPA04004998A/es unknown
-
2004
- 2004-05-26 ZA ZA200404113A patent/ZA200404113B/xx unknown
- 2004-06-25 NO NO20042697A patent/NO20042697L/no not_active Application Discontinuation
-
2005
- 2005-11-18 JP JP2005334633A patent/JP2006131638A/ja active Pending
-
2008
- 2008-09-19 US US12/234,361 patent/US20090087440A1/en not_active Abandoned
-
2009
- 2009-12-01 JP JP2009274004A patent/JP2010053140A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| NO20042697L (no) | 2004-06-25 |
| ZA200404113B (en) | 2006-03-29 |
| JP2006131638A (ja) | 2006-05-25 |
| AU2002359516B2 (en) | 2006-02-02 |
| NZ565420A (en) | 2009-09-25 |
| US20030138413A1 (en) | 2003-07-24 |
| US20090087440A1 (en) | 2009-04-02 |
| CA2468320A1 (en) | 2003-06-05 |
| CN1617742B (zh) | 2010-10-27 |
| BR0214457A (pt) | 2006-11-21 |
| CN1617742A (zh) | 2005-05-18 |
| TW200303759A (en) | 2003-09-16 |
| HUP0500999A2 (en) | 2007-11-28 |
| WO2003045431A3 (en) | 2004-01-22 |
| EP1450858A2 (en) | 2004-09-01 |
| JP2006502080A (ja) | 2006-01-19 |
| WO2003045431A2 (en) | 2003-06-05 |
| AU2002359516A1 (en) | 2003-06-10 |
| JP2010053140A (ja) | 2010-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002359516B2 (en) | Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist | |
| Chakraborty et al. | Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy | |
| Jeon et al. | Toll-like receptor agonists as cancer vaccine adjuvants | |
| Krieg | Development of TLR9 agonists for cancer therapy | |
| US9950025B2 (en) | Compositions and methods for treatment of neoplastic disease | |
| KR20150022996A (ko) | 암 면역요법을 위한 조성물 및 방법 | |
| CN106687122B (zh) | β-葡聚糖与影响肿瘤微环境的抗癌剂的组合 | |
| Crittenden et al. | Intratumoral immunotherapy: using the tumour against itself | |
| JP2011026328A (ja) | オリゴヌクレオチド組成物および免疫応答の調節のためのそれらの使用 | |
| US12447201B2 (en) | Immunogenic compounds for cancer therapy | |
| Wang et al. | Programmed polymersomes with spatio-temporal delivery of antigen and dual-adjuvants for efficient dendritic cells-based cancer immunotherapy | |
| Yan et al. | Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles | |
| US20180117176A1 (en) | Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumor immunity | |
| CN101161288B (zh) | 寡核苷酸增强的肿瘤细胞裂解物及其在制备治疗肿瘤的药物中的应用 | |
| AU2006200116B2 (en) | Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist | |
| CN118541164A (zh) | 核酸组合物及其用途 | |
| CN109563481B (zh) | 用于优化宿主抗原呈递和宿主抗肿瘤和抗病原体免疫的平台和方法 | |
| Meini | Antitumor activity of locoregional combined CpG-ODN therapy in experimental carcinoma models |